Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Asenapine (1) ·
Chlorpromazine (1) ·
Droperidol (1) ·
Fluphenazine (1) ·
Iloperidone (1) ·
Lisdexamfetamine (dimesylate) (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Modafinil (1) ·
Molindone (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Pimozide (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Trifluoperazine (1) ·
Ziprasidone (1)
brand:
Fanapt (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Orap (1) ·
Prolixin (1) ·
Provigil (US, 100 mg and 200 mg tablets); Alertec (Canada); Modiodal (France, original market). See also: Armodafinil (Nuvigil), the R-enantiomer, a related eugeroic approved 2007 with a longer effective half-life. (1) ·
Saphris (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1) ·
Vyvanse, Elvanse (EU) (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Thioxanthene D2 antagonist (1) ·
'"`UNIQ--vote-00000013-QINU`"' Once converted, dextroamphetamine acts by displacing dopamine and norepinephrine from presynaptic vesicles via VMAT-2 and reversing DAT and NET transport, the shared mechanism of all amphetamine-class agents'"`UNIQ--ref-00000014-QINU`"'. (1) ·
'"`UNIQ--vote-00000049-QINU`"' (1)
starting dose:
None (15) ·
ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day (1) ·
Narcolepsy/OSA: 200 mg PO once daily in the morning. Shift work disorder: 200 mg PO approximately 1 hour before the start of the work shift. Lower starting dose (100 mg) can be considered in elderly patients or those with hepatic impairment. (1)
preparations:
fda max:
routes:
onset:
None (15) ·
1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells) (1) ·
Peak plasma concentrations 2-4 hours after oral dose. Wakefulness-promoting effect onset correlates with peak plasma; subjective alertness typically reported within 1-2 hours of dosing. (1)
duration:
None (15) ·
10-12 hours (smoother profile than immediate-release amphetamine salts) (1) ·
Effective wakefulness promotion through approximately 12-15 hours reflecting the half-life of the predominant R-enantiomer. For shift-work use, 200 mg taken 1 hour before shift provides coverage through most 8-12 hour shifts. (1)
halflife:
bioavailability:
pregnancy:
Showing below up to 17 results in range #1 to #17.